Premier Alternatives

bit.bio

Biotechnology · Cambridge, United Kingdom · Founded 2016 · Privately Held (backing)

Developer of a synthetic biology platform designed to provide human cells for research, drug discovery and cell therapy. bit.bio is based in Cambridge, United Kingdom and was founded in 2016. It was valued at $546 million at its later-stage round in Dec 2021, the last priced event on record. It has raised $234 million across 1 recorded round; the latest was a $138 million later-stage round in Dec 2021.

PMV mark · valuation
$546.3M
Oct 2026
Priced at
its later-stage round
Dec 2021
Total raised
$234.2M
Last round
Later Stage VC
Dec 2021

bit.bio key facts

as of Oct 2026
  • Developer of a synthetic biology platform designed to provide human cells for research, drug discovery and cell therapy.
  • bit.bio is valued at approximately $546.3M as of Oct 2026, set at its later-stage round, Dec 2021; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $234.2M across 1 recorded rounds; the latest was Later Stage VC ($138.3M) in Dec 2021.
  • Notable investors include Innovate UK, Metaplanet Holdings, Tech Nation Group, Puhua Capital, Charles Songhurst — 35 tracked in total.
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$546.3M

Valued at $546.3M at its later-stage round, Dec 2021. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of bit.bio with a free account
  • ·The complete investor list: 35 names
  • ·Watch bit.bio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

bit.bio funding rounds

1 rounds
Dec 2021Later Stage VC$138.3M▮
Full funding history →

bit.bio valuation

bit.bio was valued at $546 million at its later-stage round in Dec 2021. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has bit.bio raised?

bit.bio has raised $234 million in total; 1 of its rounds is on record. The largest on record was a $138 million later-stage round in Dec 2021.

bit.bio investors

35 investors are on record for bit.bio, including Innovate UK, Metaplanet Holdings, Tech Nation Group and Puhua Capital. By type, the record holds 7 venture capital firms and 2 hedge funds. The later-stage round in Dec 2021 drew 18 investors.

Comparable companies

Comparable biotechnology names by valuation on PrivateMarketView: DNA Script ($660 million), Odyssey Therapeutics ($638 million) and Profluent ($525 million).

About bit.bio

Developer of a synthetic biology platform designed to provide human cells for research, drug discovery and cell therapy. The company applies a patented safe-harbor gene-targeting approach to inducibly express transcription factor combinations that reprogram human induced pluripotent stem cells (iPSCs) into defined and mature human cell types, enabling scientists to improve research and drug discovery, reduce costs, and extend the applications of cell therapies.

Industry
Biotechnology
Sector
Healthcare
HQ
Cambridge, United Kingdom
Founded
2016
Employees
162
Website
bit.bio/
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.